Foff Erin Pennock 4

What Happened

• Erin Pennock, Chief Medical Officer of MapLight Therapeutics (MPLT), reported open‑market sales totaling 3,213 shares across transactions on April 15–16, 2026. The reported tranches: 2,044 shares @ $26.84 (proceeds $54,861), 288 shares @ $27.01 (proceeds $7,779), and 881 shares @ $27.49 (proceeds $24,219). Total proceeds across the reported sales are about $86,859.
• The filing notes these dispositions include shares sold to cover statutory tax withholding obligations in connection with the vesting of restricted stock units (RSUs), indicating these were routine tax‑related sales rather than new purchases.

Key Details

• Transaction dates and reported prices: 2026-04-15 (2,044 @ $26.84), 2026-04-16 (288 @ $27.01; 881 @ $27.49).
• Total shares sold: 3,213; total proceeds: ~$86,859.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes: sale(s) to satisfy tax withholding on RSU vesting (F1); filing includes weighted‑average price notes and ranges for the multiple underlying trades and offers to provide per‑price breakdown on request (F2, F4, F5). The filing also notes 155 shares acquired under the issuer’s employee stock purchase plan on Mar 31, 2026 (F3).
• Filing timing: Form 4 was filed 2026-04-17 for transactions on 4/15–4/16; no late filing indication provided.

Context

• These transactions are coded as sales (S) and were carried out in the open market. Because the filing specifies the sales were done to cover tax withholding tied to RSU vesting, they are generally considered routine administrative disposals rather than clear signals of the insider’s view of the company’s stock.
• For retail investors, purchases by insiders can be more informative than routine withholding sales. If you want the per‑trade price breakdown within the reported ranges, the reporting person has offered to provide that detail on request (per footnotes).